Advertisement

Association Between Weight Promoting Medication Use and Weight Status Among Children and Adolescents in the United States

      Abstract

      Objectives

      The objectives of this study were to 1) examine the prevalence of prescription medication use overall and 2) examine the association between weight promoting medication (WPM) use by therapeutic class and weight status among a nationally representative sample of the children and adolescents in the United States. This study also further investigated antidepressant medication use among this population.

      Methods

      This cross-sectional study used data from the National Health and Nutrition Examination Survey from 2013 to 2018. Children and adolescents ages 2 to 19 years were included in this study.

      Results

      Of the 68,057,468 derived participants (34,507,154 [50.7%] male; 33,564,059 [49.3%] aged 2–10 years; 34,905,058 [51.3%] non-Hispanic White), 14,895,618 (22.2%) used a prescription medication in the prior 30 days, 21.7% (3,235,323) of which were considered weight promoting. There was no significant difference between weight status and WPM use for overall prescription medication use. Nevertheless, for overall antidepressant medication use, those with obesity were less likely to be prescribed antidepressant WPM when compared to those with normal weight (adjusted odds ratios 0.4; 95% confidence interval 0.2–0.7).

      Conclusions

      These findings suggest that although there was no significant association between WPM use and weight status overall when examining the association by therapeutic class, most children with obesity were not using antidepressant WPM. This is reassuring and potentially an active attempt at avoiding the use of medications that have an exacerbating effect on weight gain. When choosing antidepressant medications, providers, parents, and patients consider the WPM effects and appropriately choose a medication best suited to the child's health status.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Academic Pediatrics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Centers for Disease Control and Prevention. Adult obesity causes and consequences. Accessed August 26, 2020. Available at: https://www.cdc.gov/obesity/adult/causes.html

      2. Centers for Disease Control and Prevention. NCHS fact sheets: National Health and Nutrition Examination Survey. Accessed August 22, 2020. Available at: https://www.cdc.gov/nchs/data/factsheets/factsheet_nhanes.htm

        • Schwartz BS
        • Glass TA
        • Pollak J
        • et al.
        Depression, its comorbidities and treatment, and childhood body mass index trajectories.
        Obesity (Silver Spring, Md). 2016; 24: 2585-2592https://doi.org/10.1002/oby.21627
        • Baeza I
        • Vigo L
        • de la Serna E
        • et al.
        The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study.
        Eur Child Adolesc Psychiatry. 2017; 26: 35-46https://doi.org/10.1007/s00787-016-0866-x
        • Han J
        • Nguyen J
        • Kim Y
        • et al.
        Effect of inhaled corticosteroid use on weight (BMI) in pediatric patients with moderate-severe asthma.
        J Asthma. 2019; 56: 263-269https://doi.org/10.1080/02770903.2018.1455853
        • Gaspari CN
        • Guerreiro CA.
        Modification in body weight associated with antiepileptic drugs.
        Arq Neuropsiquiatr. 2010; 68: 277-281https://doi.org/10.1590/s0004-282x2010000200024
        • Novak GP
        • Maytal J
        • Alshansky A
        • et al.
        Risk of excessive weight gain in epileptic children treated with valproate.
        J Child Neurol. 1999; 14: 490-495https://doi.org/10.1177/088307389901400802
        • Riley M
        • Hernandez AK
        • Kuznia AL.
        High blood pressure in children and adolescents.
        Am Fam Physician. 2018; 98: 486-494
        • Hales CM
        • Gu Q
        • Ogden CL
        • et al.
        Use of prescription medications associated with weight gain among US adults, 1999-2018: a nationally representative survey.
        Obesity (Silver Spring, Md). 2022; 30: 229-239https://doi.org/10.1002/oby.23299
        • Perou R
        • Bitsko RH
        • Blumberg SJ
        • et al.
        Mental health surveillance among children–United States, 2005-2011.
        MMWR Suppl. 2013; 62: 1-35
        • Jonas BS
        • Gu Q
        • Albertorio-Diaz JR.
        Psychotropic medication use among adolescents: United States, 2005-2010.
        NCHS Data Brief. 2013; (PMID: 24314102): 1-8
        • Jallon P
        • Picard F.
        Bodyweight gain and anticonvulsants: a comparative review.
        Drug Saf. 2001; 24: 969-978https://doi.org/10.2165/00002018-200124130-00004
        • Brady TM.
        Obesity-related hypertension in children.
        Front Pediatr. 2017; 5: 197https://doi.org/10.3389/fped.2017.00197
        • Chirdkiatgumchai V
        • Xiao H
        • Fredstrom BK
        • et al.
        National trends in psychotropic medication use in young children: 1994-2009.
        Pediatrics. 2013; 132: 615-623https://doi.org/10.1542/peds.2013-1546
        • Johnson VR
        • Cao M
        • Czepiel KS
        • et al.
        Strategies in the management of adolescent obesity.
        Curr Pediatr Rep. 2020; 8: 56-65https://doi.org/10.1007/s40124-020-00214-9
      3. National Center for Health Statistics. NHANES survey methods and analytic guidelines. Accessed August 26, 2020. Available at: https://wwwn.cdc.gov/nchs/nhanes/analyticguidelines.aspx

      4. National Center for Health Statistics. NHANES data documentation, codebook, and frequencies: prescription medications. Accessed August 26, 2020. Available at: https://wwwn.cdc.gov/Nchs/Nhanes/2017-2018/RXQ_RX_I.htm

        • Apovian CM
        • Aronne LJ
        • Bessesen DH
        • et al.
        Pharmacological management of obesity: an endocrine Society clinical practice guideline.
        J Clin Endocrinol Metab. 2015; 100: 342-362https://doi.org/10.1210/jc.2014-3415
        • Cardel MI
        • Atkinson MA
        • Taveras EM
        • et al.
        Obesity treatment among adolescents: a review of current evidence and future directions.
        JAMA Pediatr. 2020; 174: 609-617https://doi.org/10.1001/jamapediatrics.2020.0085
        • Srivastava G
        • Apovian CM.
        Current pharmacotherapy for obesity.
        Nat Rev Endocrinol. 2018; 14: 12-24https://doi.org/10.1038/nrendo.2017.122
        • Czepiel KS
        • Perez NP
        • Campoverde Reyes KJ
        • et al.
        Pharmacotherapy for the treatment of overweight and obesity in children, adolescents, and young adults in a large health system in the US.
        Front Endocrinol (Lausanne). 2020; 11: 290https://doi.org/10.3389/fendo.2020.00290
        • Goldstein TR
        • Goldstein BI
        • Mantz MB
        • et al.
        A brief motivational intervention for preventing medication-associated weight gain among youth with bipolar disorder: treatment development and case report.
        J Child Adolesc Psychopharmacol. 2011; 21: 275-280https://doi.org/10.1089/cap.2010.0104
        • Leslie WS
        • Hankey CR
        • Lean ME.
        Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review.
        QJM. 2007; 100: 395-404https://doi.org/10.1093/qjmed/hcm044
        • Jeffery E
        • Church CD
        • Holtrup B
        • et al.
        Rapid depot-specific activation of adipocyte precursor cells at the onset of obesity.
        Nat Cell Biol. 2015; 17: 376-385https://doi.org/10.1038/ncb3122
        • Spalding KL
        • Arner E
        • Westermark PO
        • et al.
        Dynamics of fat cell turnover in humans.
        Nature. 2008; 453: 783-787https://doi.org/10.1038/nature06902
        • Malone M.
        Medications associated with weight gain.
        Ann Pharmacother. 2005; 39: 2046-2055https://doi.org/10.1345/aph.1G333
        • Rubin MB
        • Miller CM
        • Bauer SC
        • et al.
        Identifying characteristics and outcomes in youth with obesity and developmental disabilities.
        Disabil Health J. 2021; 14100988https://doi.org/10.1016/j.dhjo.2020.100988
        • Skinner AC
        • Ravanbakht SN
        • Skelton JA
        • et al.
        Prevalence of obesity and severe obesity in US children, 1999-2016.
        Pediatrics. 2018; 141e20173459https://doi.org/10.1542/peds.2018-1916
        • Tester JM
        • Phan TT
        • Tucker JM
        • et al.
        Characteristics of children 2 to 5 years of age with severe obesity.
        Pediatrics. 2018; 141: e20173228https://doi.org/10.1542/peds.2017-3228
        • Skinner AC
        • Perrin EM
        • Moss LA
        • et al.
        Cardiometabolic risks and severity of obesity in children and young adults.
        N Engl J Med. 2015; 373: 1307-1317https://doi.org/10.1056/NEJMoa1502821
        • Rundle AG
        • Factor-Litvak P
        • Suglia SF
        • et al.
        Tracking of obesity in childhood into adulthood: effects on body mass index and fat mass index at age 50.
        Child Obes. 2020; 16: 226-233https://doi.org/10.1089/chi.2019.0185
        • Correll CU.
        Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials.
        J Am Acad Child Adolesc Psychiatry. 2007; 46: 687-700https://doi.org/10.1097/chi.0b013e318040b25f
        • Correll CU
        • Lencz T
        • Malhotra AK.
        Antipsychotic drugs and obesity.
        Trends Mol Med. 2011; 17: 97-107https://doi.org/10.1016/j.molmed.2010.10.010
        • Maayan L
        • Vakhrusheva J
        • Correll CU.
        Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis.
        Neuropsychopharmacology. 2010; 35: 1520-1530https://doi.org/10.1038/npp.2010.21
        • Olfson M
        • Druss BG
        • Marcus SC.
        Trends in mental health care among children and adolescents.
        N Engl J Med. 2015; 372: 2029-2038https://doi.org/10.1056/NEJMsa1413512
        • Quek YH
        • Tam WWS
        • Zhang MWB
        • et al.
        Exploring the association between childhood and adolescent obesity and depression: a meta-analysis.
        Obes Rev. 2017; 18: 742-754https://doi.org/10.1111/obr.12535
        • Serretti A
        • Porcelli S.
        Antidepressant induced weight gain.
        BMJ (Clinical Research ed). 2018; 361: k2151https://doi.org/10.1136/bmj.k2151
        • Wu RR
        • Zhao JP
        • Jin H
        • et al.
        Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
        JAMA. 2008; 299: 185-193https://doi.org/10.1001/jama.2007.56-b
        • Wang M
        • Tong JH
        • Zhu G
        • et al.
        Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study.
        Schizophr Res. 2012; 138: 54-57https://doi.org/10.1016/j.schres.2012.02.021
        • Funk LM
        • Shan Y
        • Voils CI
        • et al.
        Electronic health record data versus the National Health and Nutrition Examination Survey (NHANES): a comparison of overweight and obesity rates.
        Med Care. 2017; 55: 598-605https://doi.org/10.1097/mlr.0000000000000693
        • Khera AV
        • Chaffin M
        • Wade KH
        • et al.
        Polygenic prediction of weight and obesity trajectories from birth to adulthood.
        Cell. 2019; 177: 587-596.e9https://doi.org/10.1016/j.cell.2019.03.028
        • Vieweg WV
        • Sood AB
        • Pandurangi A
        • et al.
        Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?.
        Acta Psychiatr Scand. 2005; 111: 177-184https://doi.org/10.1111/j.1600-0447.2004.00444.x